Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?

Area of Science:

• Cardiology
• Clinical Guidelines
• Risk Assessment

Background:

• International guidelines recommend CHA₂DS₂-VASc and HAS-BLED scores for stroke and bleeding risk in atrial fibrillation (AF) patients.
• Accurate risk stratification is crucial for managing AF patients and preventing thromboembolic events and bleeding complications.

Purpose of the Study:

• To review and highlight the recent updates in the CHA₂DS₂-VASc and HAS-BLED scoring systems for AF patients.
• To emphasize the dynamic nature of stroke and bleeding risks and the importance of regular reassessment.

Main Methods:

• Analysis of the 2020 European Society of Cardiology (ESC) AF guidelines.
• Review of updated definitions for components of CHA₂DS₂-VASc and HAS-BLED scores.

Main Results:

• The CHA₂DS₂-VASc score now includes both HFpEF and HFrEF (1 point) and hypertrophic cardiomyopathy.
• The "Vascular diseases" component of CHA₂DS₂-VASc was expanded to include prior myocardial infarction and angiographically significant coronary artery disease.
• A high HAS-BLED score necessitates addressing modifiable bleeding risk factors and closer follow-up, not automatic discontinuation of anticoagulation.

Conclusions:

• Recent guideline revisions refine stroke and bleeding risk assessment in AF patients.
• Regular reassessment of stroke and bleeding risks is essential.
• Future research may incorporate AF duration and left atrial function for personalized risk evaluation.